These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26765074)

  • 1. Adverse event monitoring of the human papillomavirus vaccines in Scotland.
    Cameron RL; Ahmed S; Pollock KG
    Intern Med J; 2016 Apr; 46(4):452-7. PubMed ID: 26765074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013.
    Šubelj M; Učakar V; Kraigher A; Klavs I
    Euro Surveill; 2016; 21(14):. PubMed ID: 27103551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events.
    Callréus T; Svanström H; Nielsen NM; Poulsen S; Valentiner-Branth P; Hviid A
    Vaccine; 2009 May; 27(22):2954-8. PubMed ID: 19428906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events following HPV vaccination, Alberta 2006-2014.
    Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
    Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events following immunization in Ontario's female school-based HPV program.
    Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
    Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase
    Chandler RE; Juhlin K; Fransson J; Caster O; Edwards IR; Norén GN
    Drug Saf; 2017 Jan; 40(1):81-90. PubMed ID: 27638661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
    Pomfret TC; Gagnon JM; Gilchrist AT
    J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus vaccine introduction--the first five years.
    Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
    Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Australian experience with the human papillomavirus vaccine.
    Garland SM
    Clin Ther; 2014 Jan; 36(1):17-23. PubMed ID: 24417782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
    de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
    Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.
    van Klooster TM; Kemmeren JM; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(28):4601-7. PubMed ID: 21549785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving high and equitable coverage of adolescent HPV vaccine in Scotland.
    Sinka K; Kavanagh K; Gordon R; Love J; Potts A; Donaghy M; Robertson C
    J Epidemiol Community Health; 2014 Jan; 68(1):57-63. PubMed ID: 23986492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
    Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
    Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring adverse events following immunisation in developing countries: experience from human papillomavirus vaccination demonstration projects.
    Jain KM; Paul P; LaMontagne DS
    Sex Health; 2013 Mar; 10(1):57-63. PubMed ID: 23237538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System.
    Borja-Hart NL; Benavides S; Christensen C
    Ann Pharmacother; 2009 Feb; 43(2):356-9. PubMed ID: 19155346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy.
    Scavone C; Di Mauro C; Brusco S; Bertini M; di Mauro G; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Expert Opin Drug Saf; 2019 May; 18(5):427-433. PubMed ID: 30907147
    [No Abstract]   [Full Text] [Related]  

  • 17. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of cervical cancer prevention: human papillomavirus vaccines.
    Cadman L
    J Fam Health Care; 2008; 18(4):131-2. PubMed ID: 18754553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions.
    Siegrist CA; Lewis EM; Eskola J; Evans SJ; Black SB
    Pediatr Infect Dis J; 2007 Nov; 26(11):979-84. PubMed ID: 17984802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
    Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.